Skip to Main Content
Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is modest. We plan to stage a listening party, tidy up the Pharmalot grounds, and promenade with the energetic official mascot. And what about you? Have you procured apples and pumpkins yet? If not, there is still time. You could boost the economy and buy some winter gear, assuming inventories are available. Or you could convince someone to get vaccinated. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

The fate of the Democratic party’s ambitious goal of allowing Medicare to negotiate drug prices rests with a handful of key moderate senators, STAT notes. Negotiations on the exact scope of the reforms heated up this week after months of stalemate. But as lawmakers push to compile an outline of the massive domestic spending package that forms a cornerstone of President Biden’s domestic agenda, consensus on drug pricing policies has proved elusive. Besides Sen. Kyrsten Sinema (D-Ariz.), the list of potential holdouts includes Sens. Tom Carper and Chris Coons, from President Biden’s home state of Delaware, and Bob Menendez of New Jersey, which is home to many drug makers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment